Methoxy polyethylene glycol-epoetin beta
Brand names: Mircera
Methoxy polyethylene glycol-epoetin beta is a long-acting, continuous erythropoietin receptor activator used to treat anaemia associated with chronic kidney disease.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It is a pegylated erythropoietin analogue that binds and activates the erythropoietin receptor, with a different receptor interaction and prolonged half-life allowing less frequent administration.
Prescribing in practice
- Avoid overcorrecting haemoglobin, as high targets increase thrombotic and cardiovascular risk; use the lowest level that avoids transfusion.
- Ensure adequate iron, folate and B12 status to support an effective haematological response.
- Monitor for new or worsening hypertension, which may require treatment.
Monitoring
Monitor haemoglobin, blood pressure and iron indices regularly and titrate the dose to maintain the target haemoglobin.
Counselling the patient
- Because it is long-acting, it is given less frequently than older erythropoietins.
- Attend blood tests so the dose can be adjusted safely.
- Report severe headache, visual disturbance or possible clot symptoms promptly.
Evidence & guidelines
This continuous erythropoietin receptor activator is licensed for renal anaemia, offering extended dosing intervals while following conservative haemoglobin targets per NICE.
Reference: NICE NG8; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.